FDA Approves MannKind's Afrezza for Pediatric Diabetes, Significantly Expanding Market
MNKD sits 71% above its 52-week low of $2.23.
Summary
MannKind secured FDA approval for its Afrezza insulin inhalation powder for children and adolescents aged 6 and older with Type 1 and Type 2 diabetes. This significantly expands the addressable market for Afrezza, potentially driving substantial revenue growth. The approval follows yesterday's news that the FDA released MannKind from a major postmarketing trial for Afrezza, building positive momentum for the drug. This regulatory win is crucial, especially after the company reported a net loss of $16.6 million in Q1 2026.
At the time of this announcement, MNKD was trading at $3.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.23 to $6.51. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.